Filing Flows

Filing Flows › Biogen (BIIB) › Next earnings date

Biogen (BIIB) earnings

Biogen (BIIB) last reported on Oct 28, 2026: revenue $2.8B for the third quarter 2026. The next date is not set yet. It beat the EPS estimate in 100% of the quarters on record.

Beat rate100%

The last report

Biogen reported revenue of $2.8B for the third quarter 2026 (+11% Y/Y), net loss $20.6M: MS Product Revenues $919M, Rare Disease Product Revenue $676M, SPINRAZA $461M, Royalty Attributed to OCREVUS $370M. How it makes money → · Every quarter →

Biogen: EPS against the estimate, last 5 reportsBiogen: EPS against the estimate, last 5 reportsEstimateReported$3.88$4.81Oct 25$1.62$1.99Feb 26$2.95$3.57Apr 26$2.03$3.60Jul 26$1.99$2.62Oct 26
Latest (Oct 26): Estimate $1.99, Reported $2.62.
BIIB: the stock's move on each reportBIIB: the stock's move on each reportOct 28, 2026-1.2%Jul 29, 2026+1.1%Apr 29, 2026+3.2%Feb 6, 2026+4.6%Oct 30, 2025+4.3%

Biogen's latest quarter

Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.

Questions

When does BIIB report earnings?

The next date is not set yet.

Does Biogen usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.